iBio(IBIO)
NEW YORK, NYBiotechnology
Focus: iBio is a publicly traded pre-revenue biotech focused on antibody therapies for oncology and metabolic disorders. With 1-50 employees and only $225K in FY2025 revenue, it operates as a clinical-stage company with three Phase 1 programs.
Profile data last refreshed 57m ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at iBio?
AI assessmentiBio offers high-risk, high-reward early-stage exposure suitable only for scientists comfortable with pre-clinical uncertainty and significant dilution risk; capital runway and lack of revenue traction warrant serious due diligence.
Why Work Here
- Early-stage antibody discovery platform with potential for significant impact if Phase 1 programs advance to clinical validation
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$225K
Pipeline & Clinical Trials
IBIO-600
Overweight , ObesityClinical Trials (1)
NCT07487376A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
Phase 1Help build intelligence for iBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.